首页> 美国卫生研究院文献>Clinical Cardiology >Tissue angiotensin‐converting enzyme inhibitors: Are they more effective than serum angiotensin‐converting enzyme inhibitors?
【2h】

Tissue angiotensin‐converting enzyme inhibitors: Are they more effective than serum angiotensin‐converting enzyme inhibitors?

机译:组织血管紧张素转化酶抑制剂:它们是否比血清血管紧张素转化酶抑制剂更有效?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Since their discovery in the 1980s, angiotensin‐converting enzyme (ACE) inhibitors have been shown to decrease angiotensin formation, prevent breakdown of bradykinin, and may also act on peptides of the renin‐angiotensin system. They are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure, and have been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure. They may preserve endothelial function and counteract initiation and progression of atherosclerosis. Broadly, ACE inhibitors can be divided into tissue specific or serum ACE inhibitors. Tissue‐specific ACE inhibitors as a group are not superior to serum ACE inhibitors in the treatment of coronary artery disease. Pending direct comparator clinical trials between a tissue ACE inhibitor and a plasma ACE inhibitor, both ramipril and perindopril can be recommended for secondary risk prevention, based on the evidence.
机译:自从1980年代发现以来,血管紧张素转换酶(ACE)抑制剂已被证明可以减少血管紧张素的形成,防止缓激肽的分解,并且还可能作用于肾素-血管紧张素系统的肽。它们可有效降低左心室收缩功能障碍或心力衰竭患者的心力衰竭,心肌梗塞和因心血管原因导致的死亡,并且已被证明可以减少无心力衰竭的血管疾病患者的动脉粥样硬化并发症。它们可以保留内皮功能并抵消动脉粥样硬化的发生和发展。广泛地,ACE抑制剂可分为组织特异性或血清ACE抑制剂。组织特异性ACE抑制剂在治疗冠状动脉疾病方面并不优于血清ACE抑制剂。根据证据,可以建议在组织ACE抑制剂和血浆ACE抑制剂(雷米普利和培哚普利)之间进行直接比较试验,以进行二级风险预防。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号